Episenta (sodium valproate) can now be prescribed to treat manic episodes in bipolar disorder when lithium is contraindicated or not tolerated. Treatment can be continued after the manic episode in patients who respond. Available as prolonged-release capsules and granules and as a solution for injection, Episenta was previously licensed only as an anti-epileptic.
The recommended initial dose for the new indication is 750mg daily in one or two divided doses. The dose should be increased as rapidly as possible to achieve the lowest effective dose, which is usually between 1g and 2g daily.
Further Information: Beacon Pharmaceuticals